{
    "clinical_study": {
        "@rank": "77054", 
        "arm_group": [
            {
                "arm_group_label": "metformin, pegylated-IFN, ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "metformin,pegylated-IFN and ribavirin"
            }, 
            {
                "arm_group_label": "Pegylated-IFN and ribavirin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "pegylated -IFN and ribavirin"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to investigate the treatment response of metformin, Peg-IFN and\n      ribavirin combination therapy for chronic hepatitis C virus (HCV)."
        }, 
        "brief_title": "Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Hepatitis c", 
            "Insulin Resistance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Insulin Resistance", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Current standard of treatment for HCV with pegylated interferon(Peg-IFN)-alpha and ribavirin\n      can achieve sustained virological response (SVR) in only 60-90% of patients. Insulin\n      resistance is an important factor of non-response to combination therapy. Metformin is a\n      insulin sensitizer and can effectively reduce insulin resistance. The aim of the study is to\n      investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy\n      for chronic HCV."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCV RNA (+) and ALT > 40 U/L\n\n          -  Compensated liver\n\n          -  HOMA-IR > 2\n\n        Exclusion Criteria:\n\n          -  neutrophil \uff1c1500/mm3\n\n          -  male: Hb < 13 g/dl, female: Hb < 12 g/dl\n\n          -  platelet < 80,000 /mm3\n\n          -  Cr > 2.5 mg/dl\n\n          -  Alcohol use > 20 gm per day\n\n          -  uncontrolled depression, thyroid disease, autoimmune disease\n\n          -  Pregnancy\n\n          -  Hepatocellular carcinoma\n\n          -  allergy to interferon or ribavirin\n\n          -  Diabetes\n\n          -  HBV/HIV co-infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664845", 
            "org_study_id": "VGHKS12-CT3-16"
        }, 
        "intervention": [
            {
                "arm_group_label": "metformin, pegylated-IFN, ribavirin", 
                "description": "metformin 500mg tid", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug", 
                "other_name": "glucophage"
            }, 
            {
                "arm_group_label": [
                    "metformin, pegylated-IFN, ribavirin", 
                    "Pegylated-IFN and ribavirin"
                ], 
                "description": "pegasys 180 mcg qw", 
                "intervention_name": "pegylated-IFN", 
                "intervention_type": "Drug", 
                "other_name": "pegasys"
            }, 
            {
                "arm_group_label": [
                    "metformin, pegylated-IFN, ribavirin", 
                    "Pegylated-IFN and ribavirin"
                ], 
                "description": "ribavirin 800-1200 mg qd according to BW", 
                "intervention_name": "ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hepatitis c", 
            "metformin", 
            "pegylated interferon"
        ], 
        "lastchanged_date": "August 13, 2012", 
        "location": {
            "contact": {
                "email": "tsaiwl@yahoo.com.tw", 
                "last_name": "Wei-Lun Tsai, MD", 
                "phone": "886-7-3422121", 
                "phone_ext": "2075"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung", 
                    "country": "Taiwan", 
                    "zip": "813"
                }, 
                "name": "Kaohsiung Veterans General Hospital"
            }, 
            "investigator": {
                "last_name": "Wei-Lun Tsai, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance", 
        "other_outcome": {
            "description": "HCV RNA At 4 weeks", 
            "measure": "RVR", 
            "safety_issue": "Yes", 
            "time_frame": "HCV RNA At 4 weeks"
        }, 
        "overall_contact": {
            "email": "tsaiwl@yahoo.com.tw", 
            "last_name": "Wei-Lun Tsai, MD", 
            "phone": "886-7-3422121", 
            "phone_ext": "2075"
        }, 
        "overall_official": {
            "affiliation": "Department of Gastroenterology, Kaohsoung Veterans General Hospital", 
            "last_name": "Wei-Lun Tsai, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HCV RNA negative 24 weeks after treatment is stopped", 
            "measure": "sustained virological response", 
            "safety_issue": "No", 
            "time_frame": "24 weeks after treatment is stopped"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664845"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaohsiung Veterans General Hospital.", 
            "investigator_full_name": "Wei-Lun Tsai", 
            "investigator_title": "Attending physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Check Serial change HOMA-IR at baseline, 4 weeks and 12 weeks after treatment", 
            "measure": "change of HOMA-IR", 
            "safety_issue": "No", 
            "time_frame": "Serial change of HOMA-IR at baseline, 4 weeks and 12 weeks after treatment"
        }, 
        "source": "Kaohsiung Veterans General Hospital.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaohsiung Veterans General Hospital.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}